EXercise Training for the Prevention of Cancer Thrombosis (EXPECT) Pilot Trial (EXPECT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01853202|
Recruitment Status : Completed
First Posted : May 14, 2013
Last Update Posted : December 4, 2014
|Condition or disease||Intervention/treatment||Phase|
|Cancer Thrombosis||Behavioral: Supervised aerobic exercise training||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||EXercise Training for the Prevention of Cancer Thrombosis (EXPECT) Pilot Trial|
|Study Start Date :||March 2013|
|Actual Primary Completion Date :||March 2014|
Experimental: Group 1 - Supervised aerobic exercise training
This group will participate in 3 supervised exercise sessions/week at an intensity of 50%-70% of the individually determined VO2max between 30-45 min/session for 12 weeks. The aerobic training intervention will closely mimic the standard exercise-based guidelines adopted in cardiac rehabilitation. All intervention sessions will be performed in a supervised setting with one-on-one supervision by an American College of Sports Medicine-certified exercise physiologist. Aerobic exercise training will be prescribed based on the guiding ACSM principles with the aim of improving VO2max. Walking was chosen because it is the preferred mode of exercise training in cancer patients.
|Behavioral: Supervised aerobic exercise training|
No Intervention: Group 2
The 12-week program will consist of monthly phone contacts to check in with patient and review their exercise log entries for that month in order to capture physical activity done outside of the intervention setting.
- Thrombin Generation [ Time Frame: 12 weeks ]The primary endpoint will be thrombin generation, a marker of VTE risk in cancer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01853202
|United States, Vermont|
|Fletcher Allen Healthcare|
|Burlington, Vermont, United States, 05401|
|Principal Investigator:||Susan G Lakoski, MD||University of Vermont|